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1. INTRODUCTION  
Dried Blood Spot (DBS) analysis has been introduced more and more into daily practice.1 To 
assure the quality of bioanalytical methods and to assure that the results obtained with those 
methods are valid, it is of utmost importance that newly developed methods are fit for 
purpose. Those methods must have undergone adequate method validation and are monitored 
via a suitable quality control (QC) program. Absence of DBS-specific method validation 
guidelines results in DBS-based methods lacking essential validation aspects with reduced 
credibility.1-4 Validation requirements described in guidelines for the quantitative analysis of 
traditional matrices (i.e. liquid blood, plasma or se um) are not always easily translated to 
analysis of dried blood spots.5,6 Moreover, several additional parameters, like volume- and 
hematocrit (HT) effects, which are not part of traditional guidelines, are often overlooked or 
not adequately assessed.7 
Therefore, this guideline aims at defining the parameters necessary for the validation of 
quantitative DBS-based methods and to provide advice on how these can be assessed. In 
addition, guidance is given on the application of validated methods in a routine context. The 
recommendations in this guideline are based on existing guidelines for traditional matrix 
analysis -in particular the bioanalytical method validation guidelines issued by the European 
Medicines Agency (EMA) and the Food and Drug Administration (FDA),5,6 the guideline for 
measurement procedure comparison provided by the Clinical and Laboratory Standards 
Institute (CLSI)8, several white papers on dried matrix analysis,9-11 as well as other published 
work and the personal experience of the authors.  
The focus of this guideline is the analysis of DBS for the quantitative determination of small 
molecule drugs and drug metabolites using chromatogr phic techniques for therapeutic drug 
monitoring (TDM) purposes. However, many elements of this guideline are also relevant for 
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dried plasma spot (DPS) analysis, as well as for the analysis of DBS for purposes other than 
TDM.  
As the successful validation of a DBS-based analytical method starts with method 
development, this guideline commences by outlining the potential pitfalls encountered during 
that stage (part 2A, 2B, 2C). Furthermore, the importance of pre-validation stress testing is 
highlighted (2D). In a next section, the actual method validation is extensively discussed (part 
3 and 4). This validation section encompasses both the analytical validation (comprising both 
the classical and the DBS-specific validation parameters) and the clinical validation (i.e. 
demonstration of equivalence between DBS-based results and results obtained in the classical 
matrix). Finally, quality control is briefly discussed (part 5). A summary of this guideline can 
be found in Supplement S-1, http://links.lww.com/TDM/A342. 
 
2. METHOD DEVELOPMENT: CONSIDERATIONS FOR SUCCESSFUL 
VALIDATION  
Before embarking on the set-up of a DBS-based procedure, it is essential to carefully think 
about the purpose of the method. Certain considerations need to be made to ensure the 
suitability of the method for a given application (i.e. to ensure the method is fit for purpose) 
already in this early stage. These considerations are discussed below, and the different 
options are schematically summarized in Figure 1. Furthermore, stress testing of the method 
during method development will allow potential issue  to be detected at an early stage, which 
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A. CONSIDERATIONS REGARDING SAMPLE COLLECTION 
Collection procedure 
Nowadays, the most frequently used dried blood sample collection method is the collection of 
a non-volumetric drop of blood (DBS), free falling or by touching onto a filter paper (i.e. 
directly from a finger prick or heel stick). Alternatively, the blood sample may be deposited 
volumetrically using a capillary or a pipette. Furthermore, several blood collection strategies 
exist in which a volumetric dried blood sample can be directly generated from a non-
volumetric drop of blood, without the use of pipettes or handheld capillaries. These strategies 
include i.e. HemaXIS12, HemaPEN®13, Capitainer14-16 and VAMS.17-19 In addition, dried 
plasma spot (DPS) may be collected rather than DBS. These DPS may be generated either by 
centrifugation of a liquid blood sample and subsequent application of an amount of plasma 
onto a filter paper or by using a device which allows in situ DPS generation.20-23   
While some of the above-mentioned collection strategies may allow patient self-sampling 
(e.g. non-volumetric DBS collection24, VAMSTM25, in situ generated DPS), other collection 
methods (e.g. volumetric DBS collection using exact volume capillaries, DPS generation 
following centrifugation) require trained professionals and/or laboratory equipment. 
Although the latter strategies are not suitable for home sampling, they may still be valuable in 
another context. DPS generation via whole blood centrifugation and pipetting may, for 
example, be a suitable approach if DPS are prepared in a laboratory in a remote or resource-
limited setting to allow more convenient transport t  a centralized or reference laboratory.26 
Additionally, other parameters such as required sample volume, automation capabilities, 
commercial availability, the cost of a given microsampling device, as well as overall costs, 
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Selection of the type of filter paper 
If samples are to be collected on filter paper, the typ  of filter paper (card) that will be used 
needs to be carefully chosen. The type of filter paper may affect the occurrence of 
interferences, the blood’s spreading behavior, sample homogeneity, as well as analyte 
stability and recovery.27-29 Commercially available filter paper can either be untreated (e.g. 
Whatman® 903, Ahlström 226, DMPK-C), or pretreated with e.g. denaturing agents or 
enzyme inhibitors (e.g. DMPK-A or DMPK-B).30 Furthermore, in certain DBS-based 
methods, in-house pretreated filter paper has been us d to increase analyte stability or 
recovery.31-34 Moreover, some types of collection devices have been r ported to be less 
affected by the HT effect and may help to overcome this issue.35,36 Additionally, chitosan and 
alginate foams have been proposed as collection substrates to help increase analyte recovery, 
as they dissolve during sample extraction.37 Although most DBS-based bioanalytical methods 
use regular, cellulose-based, untreated filter paper (cards), for certain applications it may be 
valuable to evaluate the use of pretreated or non-cellulose-based alternatives. However, it 
needs to be kept in mind that the use of non-commercially available substrates may hinder a 
generalized application of the method and requires in-house assessment of batch to batch 
quality.38 
Interferences originating from the collection substrate 
It is advised to analyze some blank collection cards during early method development to 
assess whether the collection material itself is blank and whether there are any interferences 
present that need to be separated chromatographically from the target compound(s).28 If one 
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The amount of sample that is required for a certain analysis will mainly depend on the 
envisaged lower limit of quantitation (LLOQ) and is inherently linked to the available 
instrumentation. However, the minimally required volume should always relate to how the 
samples are collected. For the set-up and validation of the method a sample volume 
representative of the sample volume of the patient samples needs to be employed. Most 
people will typically generate DBS of 20 to 70 µL if free falling drops of blood are collected, 
whereas somewhat smaller DBS-typically 15 to 50 µL-will be obtained if a hanging blood 
drop is collected by bringing it into contact with the filter paper. With the latter approach, it is 
essential that only the blood drop and not the fingertip touches the filter paper. If a DBS is 
smaller than what is typically expected, this may be an indication that the fingertip came into 
contact with the filter paper. On the other hand, if a DBS is larger than expected, multiple 
drops were likely collected. Obviously, whenever samples are collected volumetrically, the 
sample volume will be determined by the employed device. If a larger volume of blood is 
required to reach the LLOQ, sometimes punch stacking is used.39 Nonetheless, the number of 
punches required for a single analysis should remain as small as possible, to limit the amount 
of good quality samples that needs to be collected and to allow incurred sample reanalysis.  
 
Drying and storage process 
A parameter that is often neglected in DBS-based methods is the impact of drying time. If the 
sample is not completely dry before putting it in a zip-locked bag for storage, microbiological 
growth may occur and compromise sample quality.40 Furthermore, improper drying might 
also affect analyte stability and recovery.41,42 Therefore, it is advised to dry samples at least 3 
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desiccant, which will remove an additional 5% of water from the dried samples.40,43 In certain 
settings, however, the required drying time may be longer, as this depends on the ambient 
temperature and humidity, the sample volume and the type of filter paper.42 In other settings, 
shorter drying times may suffice. Therefore, it is relevant to evaluate during early method 
development whether the drying time is adequate under the conditions likely to be 
encountered during the collection of the patient samples. This evaluation is preferably 
performed using DBS with a HT in the upper range of the HT of the target population and, if 
applicable, a large sample volume, as these will dry the slowest.27 Furthermore, the ambient 
temperature and humidity during drying have been suggested to affect DBS homogeneity 
(although this effect also depends on the type of filter paper that is used).44 Similarly, also the 
storage conditions should mimic the ambient conditions encountered during patient sample 
transport/storage.45 
 
B. CONSIDERATIONS REGARDING SAMPLE PREPARATION  
Punch size 
For volumetric DBS applications, the punch size needs to be large enough to punch out the 
entire DBS, independent of the HT of the sample. Hence, it is advised to select the required 
punch size based on samples with a HT of approximately 0.15, since this HT level will be 
lower than the lowest HT level of the patient population and will therefore yield DBS that are 
(slightly) larger than the largest expected patient DBS. The punches can either be made after 
application of the blood spot to the substrate or in advance.46-48 For non-volumetric DBS 
applications, partial DBS punches are made that exclude the outer edge of the sample. If 
relatively small punches are made (≤ 4 mm or approximately 5.7 µL), most patients should be 
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may be required to obtain the desired LLOQ to increase method accuracy and imprecision or 
to exclude DBS homogeneity issues. Although generating larger DBS will be somewhat more 
difficult for a patient, when properly educated and trained, the vast majority of patients will 
be able to provide at least 1 or 2 samples that are larg  enough to make punches up to 8 mm 
(± 20 µL). The latter will also be easier if falling-drop-collection is used rather than hanging-
drop-collection. 
 
Internal standard incorporation 
Ideally, an internal standard (IS) is mixed homogenously with the biological sample before 
sample preparation to compensate for any variability throughout the entire analytical process. 
Unfortunately, this is difficult to achieve with a DBS. For DBS analysis, the closest 
alternative is to spray the IS evenly onto the sample prior to extraction.49 However, this 
requires the availability of a validated dedicated spraying system, which is not available in 
the majority of laboratories. Another option is to pre-coat the filter paper with the IS.50 
However, in that case the IS needs to be applied to a larger surface, as it is not known where 
exactly the sample will be deposited. Furthermore, th  IS should be stable for a sufficiently 
long period of time (i.e. during sample collection, transport, storage and analysis). In 
addition, the same batch of IS solution should be used for calibrators, QCs and patient sample 
collection cards, which is not feasible on a large scale. Another potential side-effect of pre-
coating filter paper with IS (in the absence of matrix) is that the IS may show different 
recovery than the target analyte. To the best of the authors’ knowledge, such strategies have 
not yet been evaluated for other dried blood samples nor has a successful application of IS-
pre-coated micro capillaries been described. Again, such an approach would require the 
availability of tailor-made devices, which will be at the expense of additional costs. In the 
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DBS punch before extraction and will hence not compensate for variability in analyte 
recovery.9,51 Therefore, analyte recovery must be investigated extensively under different 
conditions (see below) during method development and validation. 
 
C. OTHER IMPORTANT CONSIDERATIONS 
Type of blood used 
For the set-up of calibration curves and internal QCs, it is from a practical point of view 
impossible to use capillary blood samples derived from a finger prick. Instead, spiked 
samples generated from venous whole blood containing an anticoagulant are used. Which 
type of blood is best suited for this purpose largely d pends on how patient samples will be 
collected. If the DBS collection device that is used to generate the patient DBS contains a 
certain anticoagulant, the venous whole blood also needs to contain that same anticoagulant. 
On the other hand, if no anticoagulant is used during the collection of the patient samples, 
theoretically, the blood used to set up the calibration curves and QCs also has to be non-
anticoagulated. Unfortunately, it is very impractical to prepare spiked samples from non-
anticoagulated blood, as blood will start coagulating almost immediately after collection. 
Therefore, in most cases, a suitable anticoagulant will have to be selected. It is essential that 
the use of this anticoagulant does not impact the obtained results and that the stability of 
calibrators and QCs reflects that of real samples. H nce, we strongly advise to compare in an 
early stage results obtained from a non-anticoagulated sample with results from patient 
samples anticoagulated with different anticoagulants.52 These blood samples should all be 
obtained venously from the same volunteer or patient at (approximately) the same time and 
should be analyzed in quintuplicate. Based upon the knowledge about the (lack of) impact of 
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example, if analytes are e.g. stabilized by oxalate/NaF, this type of blood should 
preferentially not be used to assess the analyte’s s ability in DBS (which in practice would 
not contain that stabilizing anticoagulant). On the other hand, if the anticoagulant stabilizes 
the analyte, and anticoagulant-containing DBS are commutable in any other way with DBS 
without anticoagulant, the former could be used for the set-up of calibrators and QCs as the 
prolonged analyte stability could help ensure consistent calibration. 
 
Preparation of spiked samples 
A first step in the preparation of spiked samples is to adjust the HT or erythrocyte volume 
fraction (EVF) of the whole blood to the desired HTvalue. For most experiments the latter 
will correspond to the mean or median HT value of the target population.53 Although there 
are several ways of preparing samples with a certain HT, the preferred procedure is to 
measure the HT of the original blood sample with a hematology analyzer and to calculate 
how much plasma needs to be added or removed to obtain the desired HT value.54 After the 
addition or removal of the plasma, it is important to measure the HT again, to assure the 
sample was prepared correctly. 
In a next step, the analyte needs to be spiked into the blood. It is important to only spike a 
limited volume of analyte solution to the blood (i.e. < 5% of the sample and preferably even 
less) to not change the nature of the sample.5 Moreover, the addition of a larger volume of 
solvent would also change the sample’s viscosity and/or cause cell lysis, thereby affecting its 
spreading behavior through the DBS filter paper. Futhermore, organic solvents may denature 
proteins. To further minimize the effect of the spiking volume on the sample’s spreading 
behavior, stock solutions can be diluted with plasm, rather than with water or another 
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should equilibrate for a sufficient amount of time at a suitable temperature to mimic the 
analytes’ in vivo RBC/plasma distribution.55 
   
D. PREVALIDATION – STRESS TESTING 
Exploratory tests 
As with a traditional bioanalytical method, several exploratory tests need to be performed to 
assess whether a developed method is good enough to proceed towards validation. As with 
any chromatographic method, several technical aspect  should be checked early on during 
method development, e.g. the absence of carryover and the influence of the sample matrix on 
the chromatographic method. Furthermore, the stability of the stock solutions used for the 
spiking of the calibrators and QCs should be guaranteed. Particular points of attention during 
prevalidation for DBS-based methods are short-term stability and extraction efficiency. 
Although DBS generally tend to improve analyte stability, this is not always the case. 
Enzymatic analyte degradation may readily occur during the drying process.56 Furthermore, 
oxidation sensitive analytes are likely to suffer from stability issues, since DBS are exposed 
to air during drying and/or storage.30 If low signals are obtained from fresh samples (e.g. 
compared to a standard solution with the same concentration), this might be due to stability 
issues during the drying process. In addition, these low signals may also be caused by matrix 
effects, poor extraction efficiency or a combination of the above. 
When using LC-MS/MS, the presence of matrix effects can be evaluated using post column 
infusion. If present, these matrix effects may be eliminated by further optimization of the 
sample preparation and/or the chromatography. Poor extraction efficiency may be due to the 
analyte’s interaction with the carrier or with endogenous matrix compounds.29,57,58 However, 
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be so straightforward.34 To get an idea about potential stability issues, existing literature 
about the stability of the analyte in whole blood or about the chemical and physical properties 
of the analyte may be a good starting point. If degradation during sample drying is anticipated 
(e.g. for compounds with a very short in vitro half-life), flash heating may improve the 
analyte’s stability (at least if the analyte is thermostable), as this inactivates the enzymes.56 
Unfortunately, this strategy is not suitable for home sampling. Nonetheless, it may help to 
figure out the cause of the poor method outcome. Other strategies to help improve the analyte 
stability may include pre-impregnating the collection substrate with anti-oxidants or 
buffers.34,59 However, these strategies may hamper generalized applic tion of the method. For 
some analytes, instability issues remain unsolved, when taking into account a restrictive time 
frame for transportation of DBS. In those cases, it hould be decided that dried blood 
sampling for that analyte is not feasible. In specific situations, a volumetrically obtained 
sample could be brought into a stabilizing sampling buffer shortly after.60 When poor 
extraction efficiency is suspected, further optimization of the extraction procedure may be 
required (i.e. the evaluation of different extraction solvents, additives and extraction 
temperatures, as well as more rigorous extraction techniques (like sonication). Furthermore, 
the use of different (pre-treated) collection cards/devices may also help to improve the 
extraction efficiency. 
At this stage, it should also be evaluated whether t  obtained results are affected by the time 
between sample collection and analysis. More particularly, the results from samples analyzed 
at T0 (typically between 30 minutes-3 hour after sample generation, depending on the 
required drying time) should be compared with results obtained at later time points, 
preferably up to 48 or 72 hours. This experiment is important since time-dependent extraction 
issues have been described.61 More specifically, if the recovery decreases for the first (couple 
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analytical results. This implies to only analyze samples older than a specified time point. 
Obviously, this strategy should not only be implemented for the patient samples, but also for 
the calibrators and QCs.  
 
Evaluation of the robustness of the extraction procedure and short-term stability 
In a next step, the robustness of the extraction prcedure should be thoroughly investigated. 
This is a crucial experiment, since in most DBS applications, the IS is not capable of 
correcting for variability in extraction efficiency. The extraction efficiency may be 
concentration, HT and time-dependent and, importantly, these parameters may also affect 
each other.41,62-64 HT-dependent extraction efficiency may be present or more pronounced at 
one concentration level compared to another.64 Similarly, time-dependent extraction 
efficiency issues may occur earlier at a more extreme HT level. 
For non-thermolabile compounds, the occurrence of HT- and time-dependent extraction 
issues can be evaluated by comparing the results from fresh DBS at low, medium and high 
HT levels (with these HT levels encompassing the HT range of the target population; e.g. 
0.20, 0.40, 0.60) with a second set of samples stored at 50-60°C for at least two days. This 
second set mimics thoroughly dried (aged) samples. Thi  experiment should be performed at 
both the low and high QC level (see Figure 2). Furthermore, to simultaneously determine the 
actual extraction efficiency at both QC levels, and to evaluate the presence of matrix effects, 
also samples spiked after extraction and standard solutions should be included in this 
experiment. Moreover, each of these samples should be analyzed in quintuplicate. 
Additionally, along with these samples, a calibration curve and QCs have to be analyzed. 
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accurate pipetting of a fixed amount of blood onto pre-punched filter paper disks to rule out 
any influence of the HT spreading effect on the amount f sample being analyzed.  
When no relevant differences (i.e. ≤15%) can be observed between the results obtained from 
fresh DBS and those stored at 50-60°C, it is unlikely storage will have an impact on 
extraction efficiency. A good outcome in this set-up may also readily indicate good stability 
under ambient conditions, although this needs to be formally evaluated during method 
validation. However, it needs to be mentioned that e latter can also be affected by other 
parameters such as humidity and exposure to sunlight. Furthermore, by comparing the results 
of the samples at the three different HT levels (both f r the fresh and the stored samples), the 
occurrence of HT-dependent extraction efficiency issues can be evaluated. Moreover, using 
the Matuszewski approach, recovery and matrix effect can be evaluated at both concentration 
levels and at three HT levels.65 While performing this experiment may seem fairly elaborate 
at first, it may prevent serious problems at a later s age, which may require a complete 
revalidation (e.g. if the extraction needs to be adapted). Moreover, if successful, the 
evaluation of matrix effect and recovery may not have to be repeated at different HT levels 
during the actual method validation, as long as the method remains unchanged. Also, the 
evaluation of short-term stability at fairly extrem storage conditions (i.e. 50-60°C) is already 
incorporated in this experiment (cfr. section 3A). 
 
For more thermo-labile compounds, a similar experimnt can be performed with samples 
stored at room temperature for two weeks instead of at 60°C for two days. Although this is a 
less harsh experiment than the previously described on , it does cover a time span in which 
most clinical samples in a laboratory will have been analyzed. Alternatively, even lower 
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for at least a couple of days, the method will not be suitable. Obviously, if satisfactory, these 
data can also be used as part of the stability data required for method validation.  
To minimize the number of samples that has to be analyzed at this stage, a simplified 
experimental set-up is suggested in Figure 3. In particular, this set-up does not include 
‘spiked after extraction’ samples or standard soluti ns, and all samples are only analyzed in 
triplicate. This simplified set-up offers the advantage that if the extraction procedure has to be 
adjusted (and consequently, this evaluation has to be repeated), the number of samples that 
needs to be analyzed will not increase drastically. However, with this experiment, recovery 
and matrix effect will still need to be evaluated at different HT levels in a separate 
experiment during method validation. 
If the results of the above-mentioned experiments are non-satisfactory, this may be due to 
instability of the target analyte or to extraction efficiency issues. If the results for the different 
HT levels differ significantly and/or substantially (i.e. >15%), this is due to a HT-dependent 
extraction efficiency issue and the extraction procedure needs further optimization. In this 
context, heated extraction, as well as the use of a mixture of organic solvents rather than a 
single organic solvent may be helpful.62,63,66,67 Furthermore, the use of a different collection 
card may also help to resolve this problem. Possibly, depending on the target population, the 
procedure can be repeated with less extreme low and high HT values, to evaluate whether 
acceptable results are obtained for a more limited HT span. 
A difference between the fresh and the stored samples, on the other hand, might be due both 
to a time-dependent extraction efficiency issue and to actual instability of the target analyte.68 
However, if this difference is not observed at all HT levels, it is unlikely that analyte 
instability is the culprit. If the difference is observed at all HT levels, it may be worthwhile to 
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In case of partial DBS analysis, it is essential to evaluate DBS homogeneity, i.e. to assess 
whether results from central punches are equivalent to peripheral (or decentral) ones.69 By 
already evaluating this parameter during pre-validation, one knows whether during the next 
experiments it is required to make a central punch or whether a peripheral punch or multiple 
punches can be made from a single DBS.  
This evaluation must be performed at two concentration levels (low QC and high QC), at 
different HT levels (low, medium and high) and at smple volumes representative of the 
anticipated patient sample volumes. Each of the evaluated conditions should be analyzed in 
quintuplicate. All samples should be compared to a calibration curve prepared with samples 
of medium HT level and average volume, of which a central punch was extracted. When both 
central and peripheral punches yield results within e standard bioanalytical acceptance 
criteria (typically, within 15% of their target value), the use of both types of DBS punches is 
considered acceptable.69 
Obviously, this experiment only needs to be conducted if a central and a more peripheral 
punch can be made from a sample, which in turn will depend on the used punch size. When 
making peripheral punches, the very outer edge of the DBS should be excluded, as this has a 
different composition than the rest of the DBS (e.g. a higher amount of red blood cells, when 
using conventional Whatman® 903 filter paper). In addition, the back of the filter paper 
should always be checked to ensure that the peripheral punch is made in a part of the DBS in 
which the filter paper is saturated. Importantly, the samples should be prepared under similar 
conditions as the patient samples, as the drying process is known to influence DBS 
homogeneity.27,70 Other parameters that may influence the equivalence between central and 
peripheral punches include the filter paper type, th  position of the DBS card during drying, 
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DBS sample). The presence of an anticoagulant on the other hand, does not seem to influence 
DBS homogeneity.27 
 
3. ANALYTICAL VALIDATION 
None of the currently existing bioanalytical validation guidelines have been set up for dried 
blood sample-based methods. Certain experiments describ d in these guidelines may not be 
applicable (e.g. freeze-thaw stability, depending o the storage and transport conditions), 
whereas others may require some refinement (see section A). Moreover, some additional 
parameters will have to be evaluated (see section B).9,71 An overview of the required 
additional investigations can be found in Table 1. These will result in a slightly larger number 
of samples that will have to be analyzed during method validation (see Table 2). Before 
starting any analytical validation, it is essential o contemplate what the desired quality of the 
method should be. Although the analytical performance requirements described in e.g. the 
FDA or EMA guidelines are widely applied and accepted, they may not always be suitable 
for DBS methodology. Depending on the analyte and the purpose of the method, these 
requirements can be set either more or less strict based on scientific evidence. In this context, 
some have suggested to use acceptance criteria based on biological variation, as is common 
practice in other areas of clinical chemistry.72 
 
A. CLASSICAL VALIDATION PARAMETERS TO BE EVALUATED 
Most of the validation parameters described in tradi ional bioanalytical method validation 
guidelines will have to be assessed for DBS-based mthods as well.5,6 Therefore, those 
documents will need to be consulted too when performing a DBS method validation. 
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parameters in the context of a DBS method, are given below. Furthermore, to assist the 
reader, a brief overview of these classical validation parameters is given in Table 3. 
 
Selectivity 
To assess the selectivity of the method, blank matrices of at least six different individuals 
should be analyzed without IS, as well as two zero samples (blank DBS extracted with 
extraction solvent containing IS). These blank samples should be obtained using the same 
sampling approach as the one that will be used to collect the patient samples. In addition, 
DBS prepared from blank blood spiked with common co-medications, metabolites, and other 
potential interferences could be tested. At this stage, it may also be worthwhile to run a few 
authentic patient samples to ascertain there is no no -anticipated co-elution of a metabolite 
that may not be available as a standard. 
 
Calibration model, accuracy and precision, measurement range 
For the evaluation of the calibration model, the lower and upper limits of quantitation (LLOQ 
and ULOQ), accuracy and precision, all experiments should be performed in accordance with 
existing guidelines.5,6 The only difference is that all calibrators, blank, zero and QC samples 
should be prepared in blood with the median HT of the target population and should have a 
volume representative of the patient samples.53 As with any bioanalytical method, the 
measurement range should be representative of the concentration range in patient samples. 
For the purpose of TDM, a calibration range minimally spanning from half of the lower end 
of the therapeutic interval to twice the upper end of the therapeutic interval should suffice. 
Furthermore, intra- and inter-card variability do not eed to be evaluated separately, as these 
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applied in a routine context, inter-batch variability should be assessed. The latter can be done 
by including cards from multiple batches in the valid tion experiments. However, if non-
certified filter paper is used, a more elaborate evaluation of the filter paper may be warranted. 
 
Dilution integrity 
Contrary to traditional liquid blood samples, DBS cannot be diluted directly. Hence, to 
analyze samples with a concentration above the measur ment range, DBS extracts are 
typically diluted with blank DBS extracts or extraction solvent. Furthermore, IS-tracked 
dilution can be performed.6,73 With this approach a higher concentration of IS is added to the 
extraction solvent, with the exact amount of IS depending on the envisaged dilution factor. 
This approach renders the dilution a volume-non-critical step. In addition, for DBS, the donut 
punch approach can be used.74 With this approach, a small central punch (i.e. smaller than the 
regular punch size for a given DBS method) is made from a DBS sample and is extracted 
simultaneously with a donut punch prepared from a blank DBS sample. This donut punch is a 
regular sized DBS punch from which a small central punch (with the same punch size as used 
for the actual DBS sample) has been removed. However, to use the latter approach 
successfully, DBS homogeneity should be adequate for the small punch size and the 
extraction efficiency should not depend on the punch size.  
 
Carryover 
Aside from classical carryover, in a DBS workflow, the punching step could be considered a 
potential source of contamination. Hence, we propose t  include in the method validation the 
processing of one or more blanks following the processing of the highest calibrator.9 To the 
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(therapeutic) drugs, although it has been observed for PCR-based methods.75 In addition, 
physical carryover between cards should be avoided by storing the cards separately. 
However, if multiple cards will be stored together, potential carryover between cards requires 
evaluation.9 The same acceptance criteria as for classical carryove  should be applied.5,6 
 
Matrix effect, recovery and process efficiency 
Matrix effect, recovery and process efficiency should be evaluated in line with the set-up 
proposed by Matuszewski et al. (also see section 2).65 For this experiment, blood from at least 
six different donors should be used and two concentration levels should be evaluated (i.e. low 
and high QC level). In addition, since it is known that the HT may strongly impact the 
recovery -and possibly also the matrix effect- it is essential to evaluate recovery and matrix 
effect at different HT levels, prepared from the blood of at least one donor. These HT levels 
should encompass the anticipated HT range of the targ t population. Alternatively, this 
experiment could also be performed using five HT levels (0.20, 0.30, 0.40, 0.50, 0.60). The 
latter set-up has the advantage that whenever the most extreme HT values do not yield 
acceptable results, a narrower, acceptable HT range (re arding recovery and matrix effect) 
may still be determined, without having to repeat the experiment. This set-up is schematically 
depicted in Figure 4. As mentioned before, to accurately perform this experiment, a fixed 
volume of blank or spiked blood needs to be applied on pre-punched filter paper discs.  
Although matrix effects are preferably as small as po sible, recovery and process efficiency 
as high as possible, the exact values are not that relevant. It is essential, though, that they are 
reproducible (i.e. relative standard deviation or % RSD within 15% after IS-normalization). It 
is relevant to note that observations by Abu-Rabie et al. suggest that extraction procedures 
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The stability assessments performed during method vali ation should be representative of the 
ambient conditions encountered during sample transport, storage and processing. Therefore, 
stability should be evaluated at room temperature (th  exact temperature depending on where 
the method will be applied) and the investigated time frame should cover the maximum 
expected time frame between sample collection, analysis and potential re-analysis. 
Furthermore, since temperatures may be significantly higher during transport (e.g. in a mail 
box in the sun during summer time), short-term stabili y at elevated temperatures (i.e. 2 or 3 
days at 50°C – 60°C, or higher temperatures depending on the country) should also be 
tested.45,76 If stability under ambient conditions is only sufficient for a couple of days (but 
long enough to allow transport to the laboratory), it may be evaluated if storage at lower 
temperatures in the lab may help stabilize the DBS until (re)analysis. 
Importantly, stability may also be affected by other parameters such as humidity and 
exposure to (sun)light, conditions which are harder to replicate in the laboratory. To evaluate 
the effect of actual sample transport, samples which are generated in the laboratory can be 
analyzed immediately after drying, after storage for a certain time under controlled conditions 
and after sending them to the laboratory via mail service. Preferably the samples are 
deposited in a mail box which is relatively far from the laboratory. Furthermore, it may be 
relevant to repeat this experiment under different weather conditions, to rule out any seasonal 
effects on the stability of the samples. Although stability is typically evaluated using spiked 
samples, it may be worthwhile to also evaluate the s ability of incurred samples, as spiked 
samples may not always display the same stability profile as actual samples.77 Additionally, 






Copyright  2019 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
Capiau/Veenhof – IATDMCT DBS guideline 
26 
 
B. DRIED BLOOD SPOT-SPECIFIC VALIDATION PARAMETERS 
The analytical validation of DBS methods requires the evaluation of several additional 
parameters (see Table 2): i.e. the volume effect, the volcano effect (i.e. DBS homogeneity) 
and the HT effect.1,9,71 It is essential that these parameters are assessed simultaneously, as 
they may affect one another. These parameters can be evaluated in a single day experiment in 
which the obtained results are compared to those obtained from the reference condition (i.e. 
central DBS punches generated from DBS of average or median volume and HT). 
Alternatively, this evaluation can be combined with the accuracy and precision experiments 
(i.e. by measuring two series of DBS samples with different volumes, different HT levels etc. 
on each of three days). The latter approach has the advantage that accuracy profiles can be 
established.78,79 Importantly, if a certain effect is observed (i.e. a relevant volume, HT or 
volcano effect) appropriate measures need to be taken to ensure patient samples are within 
the validated limits and patient results are reliable. Obviously, it should also be demonstrated 
that these measures are indeed adequate. 
 
Volume effect 
The volume range in which DBS-based results are still acceptable should be defined during 
method validation. Typical volume ranges to be evaluated are 10-50 µl for hanging-drop-
collection and 20-70 µl for falling-drop-collection. The volume effect should also be 
evaluated at low (0.30), medium (0.40) and high (0.50) HT and at both low and high QC as 
shown in Figure 5. Whether a sufficient volume is collected from a patient should always be 
evaluated in the laboratory before DBS analysis. This evaluation should be performed based 
on the diameter of the DBS. More particularly, the diameter of the patient DBS should be 
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the diameter of the DBS prepared from the largest validated volume at high HT. To help 
patients to collect DBS of adequate volume, filter paper with two concentric circles may be 
used (see Figure 5).80 These circles should correspond to the minimally required volume and 
the maximally allowed volume (also taking into account different HT levels, as described 
above).80 It should be noted, however, that this type of filter paper is not commercially 
available. Furthermore, although these circles may be printed onto commercially available 
filter paper, it should be considered that the printing itself may affect the analysis 
(interferences from ink or toner, potential effect on blood flow e.g. caused by paper 
compression or wax-like materials present in toner). Therefore, the printed filter paper should 
be used during the entire method validation. Alternatively, equivalence between the in-house 
printed filter paper and the filter paper used during validation should be demonstrated at both 
low and high QC levels, and at low, medium and high volume and HT. In addition, the 
volcano effect might have to be re-evaluated, depending on the DBS punch size. Another 
option is to use a phone app to assess whether the generated DBS are within the validated 
volume ranges.81 Again, correct performance of the app should be verified during method 
validation using samples of known volume, covering the entire validated volume and HT 
range. 
 
Volcano effect  
Spot homogeneity should be evaluated when embarking upon partial-spot analysis (also see 
part 2, pre-validation). If a relevant volcano effect is observed (e.g. punches from the central 
part of the spot yield different analytical results then punches from edges of the spot), only 
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As mentioned before, it is important to actually determine the HT of the calibrators and the 
samples used during method validation. This will assure the exact HT value and, 
consequently, the validated HT range. At least three HT levels should be evaluated, more 
particularly, a QC generated with blood that has the same HT as the blood that was used to 
generate the calibrators, bracketed by HT values that encompass the expected patient HT 
range. At each HT level, two concentrations should be tested. The HT range that needs to be 
evaluated depends on the target population (see Figure 6). For a quasi-universal method, the 
range should span from 0.20 to 0.65, although a narrower range will suffice for most 
applications.80 The exact range will depend on the target population and should encompass at 
least 95% of the target population.53 
Unless no relevant HT effect is observed over the entire HT range (both during analytical and 
clinical validation, cfr. part 4) or unless it is reasonable to assume that all patient HT values 
will be within the validated HT range, a method should be used to assess the HT of the 
patient samples. Besides confirming that the HT of the patient sample effectively lies within 
the validated HT range, this may also allow to perform a HT correction, to alleviate the HT 
bias.82,83 Other options are to use volumetric dried blood samples (if there is no HT effect on 
recovery or matrix effect) or DPS (if there is no HT effect on DPS generation).36 
 
C. VALIDATION OF ONLINE DBS ANALYSIS 
Whether the sample preparation and analysis are performed online or not does not affect the 
validation parameters that need to be evaluated. The way in which certain parameters (more 
particularly, recovery, matrix effect and process effici ncy) are evaluated, however, will need 
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Recovery is typically evaluated by comparing the peak areas from blank matrix samples 
spiked before extraction with the peak areas from blank matrix samples spiked after 
extraction. However, with an online sample preparation procedure, there is no option to spike 
the samples after extraction. Instead, the analytes ar  introduced to the system during the 
extraction step. Depending on the type of system used, this can be done via the IS loop or by 
spiking the extraction solvent. The results of the samples spiked during extraction are then 
compared to those of DBS samples containing the same absolute amount of analyte. This 
requires the entire DBS to be analyzed. When adding the analyte during extraction, the 
analyte passes through the filter paper and dried blank blood matrix, during which, 
theoretically, some analyte adsorption may occur. If such adsorption occurs, this will yield a 
falsely lowered ‘100% extracted’ reference value, which in turn will result in an 
overestimation of the analyte’s recovery. Alternatively, recovery may be evaluated by 
comparing the peak area resulting from a single extraction with the sum of peak areas 
resulting from, for example, 10 consecutive extractions. It needs to be considered that even 
after 10 extractions, not all the analyte may be extracted, again leading to an overestimation 
of the recovery. Moreover, these multiple extractions may technically not be possible because 
of filter paper deterioration (depending on the type of filter paper used). 
For the evaluation of the matrix effect, the peak areas resulting from the analysis of blank 
DBS samples and blank DBS cards can be compared. In both cases the analyte will be 
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4. CLINICAL VALIDATION 
It is generally accepted that a DBS sampling method can only be implemented in the routine 
care for the purpose of TDM  ̶  and thereby (partly) replacing the standard venous whole 
blood sampling with blood, serum or plasma analysis  ̶  after it has been successfully 
validated in a clinical validation study.1,88-91 In a clinical validation study, paired DBS and 
venous blood, plasma and/or serum samples are obtained nd analyzed. The analytical results 
are compared and statistically evaluated. The purpose of a clinical validation is to 
demonstrate that results from DBS are interchangeable with those obtained with the standard 
method used for TDM, i.e. a blood, serum or plasma an lysis. The aim of this part of the 
guideline is to provide recommendations on how to clinically validate a DBS assay for TDM 
in daily practice. Current recommendations regarding clinical validation are largely based on 
published clinical validation studies that used genuine finger prick blood-derived DBS, paired 
DBS and traditional matrix samples from at least 20 patients, and appropriate statistical 
analysis to compare both methods.90-102 
 
Concentration range, number of clinical samples and patients 
The concentration range that needs to be covered during clinical validation depends on the 
sampling time points of interest (i.e. trough, peak) nd the shape of the pharmacokinetic time 
curve of a particular drug and the intra- and/or interi dividual variability.2 The CLSI 
guideline states that at least 40 patient samples should be analyzed for a clinical validation, 
ideally covering the entire measuring interval of the measurement procedures.8 This sample 
size is based on linear regression described by Linnet et al.103 The sample size that is 
necessary mostly depends on the coefficient of variation (CV%) of the method and the range 
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> 5% and a range ratio > 25, the number of samples ne ded following Linnet’s calculation 
will always be 36 or 45. Therefore, using fewer than 40 samples is only possible if the CV% 
of the method is <5% and/or the range ratio <25. Depending on the situation, these 40 
samples could either be paired capilarry DBS-venous blood samples from at least 40 different 
patients collected at a single time point (i.e. trough or peak), or paired samples taken at 2-3 
time points and from a smaller cohort, covering the w ole concentration range of interest.8,103 
Ideally, a total of 80 samples obtained from at least 40 different patients should be acquired 
for validation. This allows using one set of 40 randomly selected samples for fitting a line 
between DBS and blood (or serum or plasma) concentrations using appropiate statistical tests 
(see next paragraphs). If required, this will deriv a conversion formula or factor to convert 
e.g. capillary DBS concentrations into venous plasm concentrations. The other set of 40 
samples can be used to validate this conversion.104 Despite the limitation of collecting 
multiple samples from the same patient this approach does not require a new cohort of 40 
subjects. If the amount of patients is limited and multiple samples from the same patient (e.g. 
trough and peak) are acquired, it is our recommendation to have a minimum of 40 samples 
from at least 25 different patients to account for variation in matrix effects. In those cases 
where there is only a limited number of paired samples available, the conversion of a 
concentration in one matrix to that of another can also be checked for by a jackknife method. 
In this approach, the original set of n samples is resampled n times by systematically creating 
all possible subsets of n-1 samples. Each of these subsets is then used to set up a conversion 
equation, which is subsequently applied to the nth sample (i.e. that sample which was not 
included in the subset that was used to set up the conversion equation).105 To assess the 
predictive performance of the conversion equation, the Median Percentage Predictive Error 
(MPPE) = median (corrected 	
	 - 		)/
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(MAPE) = median (corrected		
	 	− 	 		)/
			) ∗ 100%	 can be calculated. These provide a measure of bias and 
imprecision, respectively. 106,107 
 
Comparing DBS concentrations to plasma or whole blood concentrations and effects of 
hematocrit 
Peripherally collected blood consists of a mixture of venous and arterial blood and interstitial 
fluids. Therefore, the drug concentration in peripherally collected blood may differ from 
venously collected blood. This effect is mostly present during the distribution phase of the 
drug. Although drugs are usually rapidly distributed hroughout the body, this process 
sometimes can take up to several hours, leading to unreliable results when samples are 
collected during the distribution phase.2,108-110 To detect a potential capillary-venous 
difference (Figure 7), the results obtained from a DBS collected from a finger prick (sample 
A) can be compared with those from a DBS prepared from venously collected blood (sample 
B). This venous blood (sample C) can be used to generate plasma (sample D). Both sample C 
and D can be compared to blood collected by finger prick (sample A). Alternatively, another 
blood sample needs to be collected at the same time point if serum (sample E) is to be 
prepared. Serum or plasma is typically used for routine TDM. It is essential that samples B 
and C should give the same result. If they do not, this points to an effect of the DBS approach 
in se.  
In vivo, drugs can bind to components of plasma or accumulate in red blood cells, leading to 
differences between observed concentrations in whole bl od (and, hence DBS) and in plasma 
(or serum, depending on the matrix that is routinely used for an analyte).98,108 The difference 
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drug in plasma relative to whole blood, the HT and the drug’s affinity for red blood cells. The 
study design may allow the generation of this blood-plasma relationship. If a blood 
concentration has to be expressed as a plasma or serum concentration for easy interpretation 
by the clinician, HT values should ideally be measured, known or calculated for each blood 
(DBS) sample. Furthermore, when acceptance limits for the HT have been set based upon the 
analytical validation, one should actually know whether the HT of a given sample effectively 
lies within these limits. When comparing capillary DBS values to reference whole blood 
values, correction factors (sometimes based on HT) can be necessary and should be derived 
from clinical validation studies comparing whole blood values to fingerprick (capillary) DBS 
values.89,91,92,95,97,111-115 
If, for a specified HT range, the analytical validat on has demonstrated that a DBS analytical 
method is independent of HT (or dependency is within acceptable analytical limits, see 
above), confirmation is required in a clinical valid tion study by plotting the differences 
between DBS results and reference method results vs the HT. The slope of the resulting curve 
should not be significantly different from zero.80 When this has been confirmed, plasma or 
serum concentrations can be calculated based on the equation derived from the Passing-
Bablok or weighted Deming regression line.91,101,116-120 If an analytical method has proven to 
be dependent on HT values during analytical and clinical validation using appropriate 
statistical tests, a conversion formula should include a correction for HT.121,122 An example is 




This will only be possible if there is a systematic effect from HT on estimated venous blood 
concentrations which is fixed within the relevant clini al range.123 If this is not the case, the 
method might not be suitable for clinical application. If an HT-dependent method is to be 
used in routine care, the HT of the DBS should ideally be known. Procedures to derive HT 
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spectroscopy52,83, near-infrared spectroscopy124 or the use of sulfolyser reagent.125 If for a 
HT-dependent method it is- because of technical or other reasons- not possible to know the 
HT of a DBS, clinical validation can be performed for a specific patient population, provided 
the HT range in that specific population is narrow and lies within the method’s acceptance 
limits (Figure 6).94,98 In many instances, the mean or median HT and range for a given patient 
population can be calculated from historical patient data.53 For a different patient population, 
it should be determined whether a new clinical validation should be performed.10,98,122 
Another approach to cope with the HT effect is whole blood spot analysis using a fixed spot 
volume. A volumetric capillary or pipet can be used to apply a fixed volume of finger prick 
blood to the filter paper.14,126,127 In this situation, no conversion formula to correct for HT is 
needed. However, it should be clear from the analytic l validation that the HT has no impact 
on recovery or matrix effects.89,91,95,97,115 Moreover, this can be at the expense of the 
simplicity of sampling and/or bring along additional costs. 
 
Statistical methods and interpretation 
Technically, a DBS clinical validation is a cross validation study because a candidate method 
(DBS-based) is compared to a reference method (blood-, serum- or plasma-based). Although 
guidelines from the EMA, FDA and CLSI include cross validation and subsequent statistical 
analysis of results, this paragraph provides additional recommendations and guidance for the 
interpretation of results.1,5,6,8 
As part of a clinical validation, the results obtained from DBS and the reference method 
should be compared using appropiate statistical tests. To compare two methods, regression 
analysis should be performed to measure the correlation, followed by an agreement and bias 
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that either Passing-Bablok or weighted Deming regression should be used instead of standard 
linear regression.8,128-130 Both approaches have been used in various clinical validation 
studies.91-102,131 Deming regression takes variability of both x and y into account, Passing-
Bablok regression makes no assumptions about the distribution of data points and is more 
resistant towards outliers.8,129,132 Various clinical validation studies have shown that t e 
absolute difference between results from a reference a d a DBS method is propoportional to 
the concentration, at least at higher concentrations. However, in these studies, sometimes 
only a few high concentration samples were available.91,96,120 Theoretically, an outlier in this 
region would impose an inflated or deflated estimate of proportional difference. In this case, a 
Passing-Bablok regression analysis is the preferred statistical method.8,133 Following 
regression analysis, a Bland-Altman difference plotshould be made to assess the agreement 
between both methods and estimate the bias.8 When using a (HT-dependent) conversion 
formula obtained from Passing-Bablok or weighted Deming regression, the Bland-Altman 
difference plot should be made using the (blood, plasma or serum) concentrations that were 
calculated from the DBS concentrations.1,91 
Most clinical validation studies show some level of bias when performing a Bland-Altman 
test. While it may seem obvious that Bland-Altman graphs should be generated and 
interpreted in a correct manner, this is not always the case.133 Several things can be deduced 
from a Bland-Altman difference plot. First, it can be observed whether there is an average 
bias between both methods and whether the 95% CI ofthis bias contains zero. Importantly, if 
the latter is not the case, it should have been formally decided beforehand what a clinically 
relevant or acceptable bias and corresponding limits of agreement (LoA) should maximally 
be. For instance, for tacrolimus, where trough concentrations in blood are usually between 5-
20 µg/L, a bias of 0.28 µg/L (LoA -0.45 µg/L – -0.12 µg/L), which is at most a bias of 5.6% 
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might.134 Second, the LoA’s can be derived from the Bland-Altman plot. Here, the same 
holds true: pre-set criteria are needed to define what concentration or % difference span 
between the LoA’s is still considered acceptable. This is a critical point that in many 
instances is lacking: e.g. whereas on average theremay be no bias between a DBS- and 
blood-based procedure, the span of the LoA’s may be too wide (implying there is too much 
variation) to be acceptable. What is considered acceptable in terms of bias or LoA will 
largely depend on the clinical setting, the lab’s internal policy, the availability of guidelines 
(e.g. RCPA criteria)135 and the drug of interest. Acceptance criteria should be decided by a 
multidisciplinary team of experts based on both clini al and analytical acceptance criteria. In 
addition, during a clinical validation, it can be investigated for each measured pair of samples 
whether the clinical decision by the healthcare provider would differ, based on the DBS 
concentration versus the concentration in the reference sample.92,93,99,136 Again, acceptance 
criteria should be stated beforehand in the study protocol. The EMA guideline states for 
cross-validation study samples, ‘the difference betwe n the two values obtained should be 
within 20% of the mean for at least 67% of the repeats’.5 It has been suggested that this 
guideline could also be aplied to assess agreement between DBS-based analytical results and 
reference results.1 For example, a study, in which for 30% of the samples a difference of 
more than 20% of the mean is observed, would theoretically fulfill the criteria put forward by 
the EMA guideline. However, this would likely be clinically unacceptable and in this case 
stricter limits of agreement would be preferred. It is also possible that, at lower 
concentrations, a maximum absolute deviation may be tolerated, while at higher 
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Type of card/paper used 
In a clinical validation study, it should be stated which type of paper or DBS card is used. 
This type of paper should be the same as the one that was used during analytical validation.29 
 
Sampling method and spot quality 
A major problem during clinical validation is that the provided DBS may be of insufficient 
quality for analysis due to incorrect sampling.42,137 Therefore, during clinical validation, the 
method of sampling and spot quality assessment by either an analyst or an automated quality 
assessment method should be mentioned in the study protocol.138,139 As drug concentrations 
are dynamic, it is important to collect all paired samples within 5-10 minutes of each 
other.91,116 Time-dependent changes in drug concentration are determined by 
pharmacokinetics and should be taken into account for the preparation of a sampling scheme. 
This is particularly relevant for drugs with a very short half-life or during the absorption and 
distribution phase of the drug. 
The sampling method that is used during clinical validation should be the same as the 
sampling method that will be used in daily practice. For example, if the method is intended 
for home sampling by patient finger prick, the DBS samples obtained for clinical validation 
should also be obtained by finger prick. Spotting of venous blood on a DBS card is only 
appropriate if in clinical practice venous blood will be spotted on DBS cards. For instance, 
this may be the case when transport of tubes of whole bl od is not possible due to instability 
of the compound or because of logistic difficulties ( .g. in remote areas or in resource-limited 
settings).58 This is highly relevant as for some analytes venous-capillary differences may, or 
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If a method is designed for home sampling, patients should ideally perform a finger prick to 
collect a DBS sample themselves during clinical validation. However, in most clinical 
validation studies, a trained phlebotomist collects or helps to collect samples, to rule out 
variability due to inexperienced sampling by the patient.91,95,97,99,116,123 Alternatively, both 
approaches can be used successively during clinical validation. 
Proper finger prick DBS sampling technique has been described earlier by the WHO, CLSI 
and in several studies11,42,131,138,140,141 and is also shown in supplemantary Figure S-2, 
http://links.lww.com/TDM/A342. In short, sampling should be done after disinfecting the 
finger without excessive ‘milking’ or squeezing of the puncture site to avoid hemolysis or 
dilution by tissue fluid. When possible, finger prick blood should fall on the sampling paper 
instead of applying the droplet of blood to the sampling paper with the finger (without 
touching the sampling paper with the finger). Both patient and phlebotomist should be trained 
before samples can be obtained. This training should inc ude practicing the whole sampling 
procedure under supervision of someone experienced i  DBS sampling using either a test kit 
or a real finger prick aided by educational material such as a movie or a written 
instruction.25,131,137,138,140 
All spots provided in a clinical validation study should be checked for quality by an 
experienced analyst or via a validated automated quality assessment method. Some 
requirements for a good quality spot depend on the analytical method and should be stated on 
beforehand, such as minimum spot size imposed by punching size. Other requirements are 
independent of the analytical method. Criteria are stated in supplementary Figure S-3, 
http://links.lww.com/TDM/A342. In short, all spots should be round, dried, consisting of one 
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Incurred sample reanalysis, duplicates and outliers 
In their guideline, the FDA mentions incurred sample reanalysis (ISR) as a validation 
parameter for DBS methods.6 In a clinical validation, ideally at least two replicate spots are 
available for analysis, to allow ISR and/or duplo analysis. However, reanalysis of the same 
spot (via a second punch) will not be possible when t  protocol involves the use of larger 
punching sizes (e.g. 6 or 8 mm).64 During clinical validation, it is recommended to analyze 2 
different spots per sample, when possible, to evaluate within-card precision which can be 
calculated as the percentage difference %*+,,-. = 0	12342	123
	123
∗ 100.5,24 
The %difference between duplicates should not be greate  than 20% of their mean for at least 
67% of the samples.5,6 In addition, ISR of the same spot is recommended when decentral 
punches may be used, provided spot homogeneity is supported by the analytical validation 
and small puch sizes (e.g. 3 mm) are used.27 
The presence of an outlier may be explained by several r asons such as contamination of the 
sample, errors in sampling, extreme drying or storage conditions during transport or 
analytical errors.42 In a clinical validation study most of the possible errors can be accounted 
for by, for instance, checking of spot quality of the sample upon arrival in the lab or checking 
and logging the drying time. When an outlier cannot be explained by such errors, the extreme 
studentized deviate technique8 or a standardized score test can be used to exclude outliers.121 
However, outliers should be discussed in the context of clinical application of the DBS 
method. Therefore, outliers require an argumented discussion considering clinical setting and 
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Clinical validation of automated analysis methods 
Automation of a DBS assay could improve DBS sample- and workflow efficiency and 
reproducibility. Several examples exist of automated (on- or off-line) DBS assays using 
techniques like online extraction and solid phase extraction.87,142,143 If an automated method 
is designed without a prior manual DBS method, the same recomendations for clinical 
validation apply. If a manual DBS assay used in clii al practice is replaced by an automated 
DBS method which is fully analytically validated, it is recommended to perform a cross 
validation including sample size of 40 samples from at least 25 different patients.5,6,8 Due to 
the nature of DBS, it will most likely be challengi in real practice to measure the same spot 
using both an on- and offline method. Therefore, if during the clinical validation the within-
card precision is found to be acceptable and two spots er finger prick DBS sample are 
provided, it is recomended to analyze one spot using the automated method and one spot 
using the manual method. Evaluation of agreement can ag in be performed by Passing-
Bablok or Deming analysis and via a Bland-Altman plot, as described earlier. 
 
Quality control 
Laboratories should participate in external QC programs if a DBS assay is implented in 
routine care or provide objective evidence for determining the reliability of their results.2,38 
Apart from a prociency test pilot for the immunosuppresant tacrolimus, no external QC 
programs are currently available for DBS assays for drugs.144 There is an urgent need for 
DBS proficiency testing programs to facilitate the uptake of DBS in routine care. Although 
external QC materials developed for the evaluation of liquid blood-based methods may be 
used to evaluate the quality of a DBS-based method, it should be taken into account that these 
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DBS of deviating sizes. Therefore, when using these materials, they should always be 
analyzed using a full spot approach.145 Furthermore, the extraction efficiency of an artifical 
matrix may always differ from the extraction efficiency of an actual sample. Since most 
external QC materials are only available for plasma an lysis and not for whole blood 
analysis, anopther option might be to remove part of the plasma of a blank whole blood 
sample and to replace it with the external QC material. The resulting blood can then be used 
to generate DBS, as was successfully applied for e.g. conventional antiepileptics.67 
 
5. CROSS-VALIDATION  
Once a DBS assay has been successfully applied in clinical practice, it is possible that 
changes have to be made to the sampling method, filter paper or analytical method. For some 
of these changes the standard guidelines for cross-validation are applicable.5,6 This part will 
focus on additional recommendations when DBS assays or sampling methods are altered.  
 
Different punch size 
As stated before (see section 2), a punch size is preferably less than 4 mm because punching 
the sample in the lab will be easier and patients do not need to produce large blood spots. 
When the desired LLOQ, accuracy and precision can be met with a different punch (e.g. 
smaller or ‘donut’ punch)74 than currently used in practice, a cross-validation study should be 
performed. If during the clinical validation the within-card precision is within analytical 
limits and two spots per sample are provided, it is reccomended to analyze 1 spot with the 
new punch size and 1 with the old punch size. In total, 40 samples of at least 25 different 
patients should be analyzed. In addition, extraction efficiency and DBS homogeneity should 
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accordingly. Although theoretically possible, we do not recommend to use a surface-based 
formula to convert a result from a small (e.g. 3-mm) DBS punch to a theoretical bigger (e.g. 
6-mm) DBS equivalent. 
 
Different type of filter paper 
In routine practice, several types of DBS filter paper are used such as the Whatman® 903, 
Whatman® FTA DMPK cards (type, A, B and C) (GE Healthcare, Chicago, IL, USA), and 
Perkin Elmer 226 cards (Ahlstrom, Helsinki, Finland).29 Although performance of the FDA-
approved Whatman® 903 (GE Healthcare, Chicago, IL, USA), and Perkin Elmer 226 paper is 
consistent and comparable in newborn screening,146 the influence of drug concentration and 
HT can lead to a difference in recovery of up to 20% between cards.29,147 This may be caused 
by the drugs’ ability to form hydrogen bonds with the cellulose paper, leading to decreased 
recoveries57, differences in spot homogeneity or differences in background signal.27 Not only 
the recovery of the analyte may be altered, also matrix, volcano, volume and HT effects may 
have changed, as well as the analyte’s stability. These parameters should all be re-evaluated 
as discussed before. Furthermore, QC samples for the new filter paper should be made using 
the same method as was done for the old filter paper.54 Both old and new QC samples should 
be analyzed and the obtained mean accuracy should be within 15%.5 The equivalence 
between both filter papers should be confirmed using a minimum of 40 samples obtained 
from at least 25 different patients. If not all parameters prove to be similar for both types of 
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Different sampling method 
Switching the sampling method will, most likely, be accompanied by some change in the 
method. For instance, it is likely that whole spot analysis rather than partial-punch analysis 
will be performed when a fixed volume of finger prick blood is deposited on a card instead of 
direct application of blood from the fingertip to the card. Moreover, it is possible that DBS-
based assays are replaced by newer alternatives such a  the earlier discussed VAMS 
technique because of the convenience of sampling and/or automation possibilities.25 
Importantly, as stated earlier, volumetric sampling does not necessarily eliminate the effect of 
HT or ageing on recovery, so this remains an important parameter to be studied.7,29,57,62,148 In 
addition, a new sampling technique might influence spot homogeneity, thereby introducing a 
possible unknown error in analytical results.27 Therefore, when changing sampling technique, 
sample vehicle or changing to whole spot analysis, it i  recommended to perform a full 
clinical validation study, comparing the new method t  the reference method, provided this 
change has been appropriately analytically validated.25 
 
6. CONCLUSION  
To successfully incorporate DBS-based methods in routine practice, good quality methods 
are a prerequisite. Since the quality of a method starts with its design, a sound method set-up 
not only ensures the method is suitable for a given application, it also increases the chances 
of a successful method validation. The quality of amethod needs to be assessed both during 
analytical and clinical validation and should be compared with pre-set acceptance criteria. 
This is the first guidance document discussing how to evaluate the quality of a DBS-based 
method. This guideline outlines which traditional and non-traditional validation parameters 
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importantly, each parameter should be evaluated in a way that reflects the real-life situation 
in which the method will eventually be applied. Furthermore, to ensure the method’s quality 
on a day-to-day basis the first QC programs for quantitative DBS-based methods have been 
established recently. It is important to keep in mid that DBS for TDM applications only has 
a future if the quality of the result can be guaranteed. A proper analytical and clinical 
validation are essential to achieve this. 
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Figure 1: Flowchart depicting different options forthe set-up of a dried-blood-spot-based 
method which can be used before setting up a dried blood spot-based procedure. The 
highlighted ‘flow path’ shows the procedure for TDM of immunosuppressants following 
home sampling by adult patients and partial spot analysis of DBS cards sent to the laboratory. 
Reprinted with permission from Anoek Houben. Copyright 2018 
 
Figure 2: Schematic set-up of the experiments needed to assess the robustness of the 
extraction procedure and short-term stability. The total amount of samples to be analyzed for 
this experiment is 100 (plus calibrators and QC samples). Reprinted with permission from 
Anoek Houben. Copyright 2018 
 
Figure 3: A simplified schematic set-up of an experim nt to assess the robustness of the 
extraction procedure and short-term stability, requiring a minimum number of samples. The 
total number of samples to be analyzed for this experiment is 36 (plus calibrators and QC 
samples). Reprinted with permission from Anoek Houben. Copyright 2018 
Figure 4: A schematic set-up for the evaluation of matrix effect (ME) and recovery (RE). The 
experiment can either be performed at five hematocrit (HT) levels or at three (i.e. without the 
grey samples). This experiment allows to evaluate wh ther ME & RE are constant for 
different matrices and for different HT levels. Each condition is analyzed in quintuplicate. 
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Figure 5: Example of filter paper with two concentric samples corresponding to the 
minimally required volume (e.g. 20 µL) and the maximally allowed volume (e.g. 50 µL), also 
taking into account different hematocrit (HT) levels. Figure adapted from Capiau et al.80 
Reprinted with permission from Anoek Houben. Copyright 2018 
 
Figure 6: Overview of the expected hematocrit (HT) range in different patient populations. 
The boxplots depict the distribution of hematocrit values per patient population. The boxes 
show the HT values between the 25th and 75th percentile, as well as the median HT value. The 
flags show the 2.5% and 97.5% percentiles. Adapted from De Kesel et al.53 Reprinted with 
permission from Anoek Houben. Copyright 2018 
 
Figure 7: A schematic overview of the samples that could be collected during a clinical 
validation study. The bold blue lines depict which samples could be compared to one another. 
The grey lines show which samples can be generated from which sampling method. 





Copyright  2019 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
Table 1: Overview of the analytical validation parameters that require additional evaluation in dried blood 
spot-based methods, and how to assess them. 






Evaluate at both high and low QC levels 
using 6 different donors, (with one donor 
evaluated at minimally 3 HT levels), with 
each condition determined in 
quintuplicate*. 
Should be reproducible, both between 
matrices and HT values 
(%RSD ≤ 15%). 
Volume effect 
Evaluate at both high and low QC levels 
and at least at 3 HT levels and 3 volumes*. 
One-way ANOVA with bonferroni post-
hoc analysis (p ≤ 0.05). 
Back calculated values deviate ≤15 % of 
medium volume. 
Hematocrit effect 
Evaluate at both high and low QC levels 
and at least at 3 HT levels*. 
One-way ANOVA with bonferroni post-
hoc analysis (p ≤ 0.05). 
Back calculated values deviate ≤15 % of 
medium HT values. 
Volcano effect 
Compare central and peripheral 
measurements. Evaluate at both high and 
low QC levels and at least at 3 HT levels 
and one volume (typically, the highest) *. 
Paired t-test (p ≤ 0.05) 
Back calculated ‘peripheral’ values deviate 
≤15% of ‘central’ values 
*HT levels should cover the entire HT range of the target population and the volumes should be representative of the 
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Table 2: An overview of the minimally required amount of analyses for the analytical validation of dried 
blood spots vs. whole blood. 
Validation 
parameter 
Amount of samples 
(dried blood spot-based) 
Amount of samples  
(liquid whole blood) 
Selectivity 
n = (6 + 6) x 1 x 1 = 12 
6 blank matrices, 6 LLOQs, 1 day, in singulo 
n = (6 + 6) x 1 x 1 = 12 
6 blank matrices, 6 LLOQs, 1 day, in 
singulo 
Calibration model 
n = 6 x 5 x 1 = 30 
6 calibrators, 5 days, in singulo 
n = 6 x 5 x 1 = 30 
6 calibrators, 5 days, in singulo 
Accuracy 
& precision 
n = 4 x 3 x 2 = 24 
4 QC levels (LLOQ, low, mid, high), 3 days, 
in duplicate 
n = 4 x 3 x 2 = 24 
4 QC levels (LLOQ, low, mid, high), 3 days, 
in duplicate 
Dilution integrity 
n = 1 x 3 x 2 = 6 
1 QC level (dilution QC), 3 days, in duplicate 
n = 1 x 3 x 2 = 6 
1 QC level (dilution QC), 3 days, in 
duplicate 
Carry-over 
n = (1 + 1) x 5 x 1 = 10 
a blank and zero sample, 5 days, in singulo 
n = (1 + 1) x 5 x 1 = 10 




n = 2x (2 x 5 x 1 x 1 x 5) + 2x (2 x 1 x 3 x 1 
x 5) + (2 x 1 x 5) = 170 
2 QC levels, 6 donors, of which 1 donor at 3 
HT levels, 1 day, in quintuplicate (spiked 
before/after) 
n = 2x (2 x 6 x 1 x 1 x 5) + (2 x 1 x 5) = 130 
2 QC levels, 6 donors, 1 HT level, 1 day, in 
quintuplicate (spiked before/after) 
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n = 2 x 1 x 4 x 5 = 40 
2 QC levels, 1 HT level, 4 points: T0, T1w, 
T2w @ RT, T2d @ 60°C, in quintuplicate 
n = 2 x 1 x 7 x 5 = 70 
2 QC levels, 1 HT level, 7 points, in 
quintuplicate:  
Bench-top stability: T0 & T24h @ RT 
Storage stability: T1w, T2w @ 4°C/-20°C 




n = 2 x 3 x 4 x 5 = 120 
2 QC levels, 3 HT levels, low, medium and 
high-volume central punch + high volume 
peripheral punch, all in quintuplicate 
N.A.  
TOTAL 412 282 
RT = room temperature, T = time point, T0 = starting point = at the minimum drying time (e.g. 2 hours) = at the 
minimum drying time (e.g. 2 hours), d = day, w = week. 
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Selectivity 6 individual blank matrices ≤ 20% of LLOQ (analyte) ≤ 5% (IS) 
Calibration model 
Use min. 6 calibrators + zero + blank. Zero 
and blank samples should not be included in 
the calibration curve.  
Back calculated concentrations ≤ 15% of 
nominal value (≤ 20% at LLOQ).  
≥ 75% of all calibrators and ≥ 50% per 
calibration level should comply. 
Accuracy 
& precision 
Evaluate at 4 QC levels:  
- LLOQ 
- Low = ≤ 3 x LLOQ 
- Medium = 30 - 50% of range 
- High = ≥ 75% of highest calibrator 
≤ 20% for LLOQ 
≤ 15% for other QC levels 
Dilution integrity 
Evaluate a dilution factor (e.g. 1:9) 
applicable to the patient samples. 
Accuracy and precision ≤ 15% 
Carry-over 
The analysis of (zero and) blank samples 
after the highest calibrator 




Evaluate at both low and high QC, using 6 
different blank matrices. 
- Recovery: spiked before/spiked after. 
- Matrix effect: spiked after/ standard 
solutions  
- Process efficiency: spiked before/ 
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standard solutions 
Stability 
Evaluate at both low and high QC levels. 
Store stability QCs under representative 
conditions for a representative time frame 
and measure against fresh calibrators.  
≤ 15% of nominal value  
(or ≤ 15% of value at T0) 















































































use whole blood with an anticoagulant 
that does not affect quantitation nor 
stability during validation







































Low or High Quality Control












































































































































































































It is essential 
that these give 
the same result. 
If they do not, 
it points to an 
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